Form 4: Enliven Therapeutics Officer Sells Shares
Insider Transaction Report
Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 5,000 shares of common stock for a weighted average price of $16.8412 per share.
Summary
- Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
- The transaction involved the disposition of 5,000 shares of common stock on December 19, 2025.
- The shares were sold at a weighted average price of $16.8412 per share, with individual trades ranging from $16.605 to $17.115.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Lyssikatos on November 15, 2024.
- Following this transaction, Mr. Lyssikatos beneficially owns 897,688 shares of common stock indirectly through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider stock sale under a Rule 10b5-1 plan, which is generally considered neutral in terms of company sentiment as it reflects personal financial planning rather than a change in company outlook.
Industry Context
This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape for Enliven Therapeutics.
Related Party Transactions
- The 897,688 shares beneficially owned by the reporting person following the transaction are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the reporting person serves as trustee.
Stakeholder Impact
- Shareholders: A minor, pre-planned insider sale is unlikely to have a significant impact on shareholder sentiment or the company's stock price.
- Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 11/15/2024 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 12/19/2025 | Date of the reported transaction (sale of common stock). |
| 12/23/2025 | Date the Form 4 was signed by Ben Hohl, by power of attorney. |
Keywords
Enliven Therapeutics, ELVN, Joseph P Lyssikatos, Chief Scientific Officer, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.